- Home
- BX vs TOVX Comparison
BX vs TOVX Comparison
Compare BX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BX
- TOVX
- Stock Information
- Founded
- BX 1985
- TOVX 2001
- Country
- BX United States
- TOVX United States
- Employees
- BX N/A
- TOVX 22
- Industry
- BX Investment Managers
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BX Finance
- TOVX Health Care
- Exchange
- BX Nasdaq
- TOVX Nasdaq
- Market Cap
- BX 144.6B
- TOVX 3.2M
- IPO Year
- BX 2007
- TOVX 2006
- Fundamental
- Price
- BX $170.84
- TOVX $1.14
- Analyst Decision
- BX Buy
- TOVX Strong Buy
- Analyst Count
- BX 20
- TOVX 1
- Target Price
- BX $162.72
- TOVX $6.00
- AVG Volume (30 Days)
- BX 3.9M
- TOVX 97.3K
- Earning Date
- BX 01-23-2025
- TOVX 11-12-2024
- Dividend Yield
- BX 2.01%
- TOVX N/A
- EPS Growth
- BX 22.28
- TOVX N/A
- EPS
- BX 2.90
- TOVX N/A
- Revenue
- BX $11,138,276,000.00
- TOVX N/A
- Revenue This Year
- BX $51.75
- TOVX N/A
- Revenue Next Year
- BX $29.82
- TOVX N/A
- P/E Ratio
- BX $58.98
- TOVX N/A
- Revenue Growth
- BX 35.11
- TOVX N/A
- 52 Week Low
- BX $114.88
- TOVX $1.14
- 52 Week High
- BX $200.96
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- BX 35.77
- TOVX 36.15
- Support Level
- BX $187.74
- TOVX $1.23
- Resistance Level
- BX $192.17
- TOVX $1.21
- Average True Range (ATR)
- BX 4.84
- TOVX 0.07
- MACD
- BX -3.04
- TOVX 0.01
- Stochastic Oscillator
- BX 17.13
- TOVX 0.00
About BX Blackstone Inc.
Blackstone is the world's largest alternative-asset manager with $1.108 trillion in total asset under management, including $820.5 billion in fee-earning assets under management, at the end of September 2024. The company has four core business segments: private equity (25% of fee-earning AUM and 30% of base management fees), real estate (35% and 39%), credit and insurance (31% and 24%), and multi-asset investing (9% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.